The latest on Janssens stock price article Investors have been waiting for Jansens stock to recover.

Investors have also been waiting to see if it will rebound.

Jansen Pharmaceuticals shares closed down $2.56 to $17.25 on Friday, a gain of roughly 10 percent.

That compares to a gain in the Nasdaq Composite of about 5 percent.

It was a solid day for the stock, but it also brought back memories of what happened to Jansus stock when the company went bankrupt in 2014.

JANSEN CEO Jens Johansen was fired after he failed to get approval from the FDA for a second and third round of the drug.

The company has struggled with the price of its drug and a lack of patients.

The stock has since been hammered by the price and is trading at less than $20 per share.

It is down about 10 percent from its high in the second quarter of last year.

JANSSEN PICTURE: How Jansuss stock fell and rebounded from the Jansson stock crisis.

Jenssen stock was trading up by about 20 percent before Friday’s announcement.

It’s up more than 70 percent since the end of 2016.

The drug has also been under scrutiny because it has not been approved by the FDA.

In 2014, the FDA ordered a second round of testing to determine whether the drug would work.

The second round was scheduled to begin in early 2018.

The FDA also found that the drug does not work as a treatment for some cancers and was deemed unsafe.

That led to a second, third and fourth round of approvals.

The third round included two more drug candidates and a third of the current batch.

That was not approved.

Jonssen is one of two U.S. drug makers that have been shut down by the U.N. Food and Drug Administration for allegedly violating federal regulations.

They are Pfizer and AstraZeneca.

JNS, the company behind the JANSSSENS drug, filed for bankruptcy in 2014 after a failed fundraising campaign to raise money for the company.

Jnsens stock plummeted during the bankruptcy auction of its assets in January 2018.

It went from trading above $20 a share in the fourth quarter of 2016 to $10.10 in the third quarter of 2017, a loss of more than 30 percent.